◆英語タイトル:Hansa Medical AB (HMED) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10161
◆発行会社(調査会社):
GlobalData
◆発行日:2018年11月
◆ページ数:52
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Hansa Medical AB (Hansa Medical) is a biopharmaceutical company that focuses on the development of novel immunomodulatory enzymes for transplantation and acute autoimmune diseases. The company’s lead project, IdeS is a proprietary antibody-degrading enzyme in late stage clinical development for kidney transplant patients. IdeS has potential for further development in other solid organ transplants and a range of acute autoimmune indications. Its preclinical assets include NiceR for recurring treatment in autoimmune disease, transplantation and cancer; and EnzE, a cancer immunotherapy. Hansa Medical out-licensed its HBP-assay (serum quantification of Heparin-Binding Protein), a novel diagnostic method to help predict severe sepsis in patients with infectious disease symptoms to Axis-Shield Diagnostics. Hansa Medical is headquartered in Lund, Sweden.
Hansa Medical AB (HMED) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Hansa Medical AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Hansa Medical AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Hansa Medical AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Hansa Medical AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Hansa Medical AB, Medical Devices Deals, 2012 to YTD 2018 10
Hansa Medical AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Hansa Medical AB, Pharmaceuticals & Healthcare, Deal Details 12
Equity Offering 12
Hansa Medical to Raise USD65.5 Million in Private Placement of Shares 12
Hansa Medical Plans to Raise USD21 Million in Private Placement of Shares 13
Hansa Medical Raises USD29.3 Million in Rights Offering 15
Hansa Medical Raises Funds through Private Placement of Shares 16
Hansa Medical Completes Rights Offering Of Shares For US$5.7 Million 17
Hansa Medical Completes Private Placement Of Shares For US$4 Million 18
Acquisition 19
Hansa Medical Acquires Immago Biosystems 19
Hansa Medical AB – Key Competitors 20
Hansa Medical AB – Key Employees 21
Hansa Medical AB – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Financial Announcements 23
Nov 01, 2018: Hansa Medical interim report July – September 2018 23
Jul 19, 2018: Hansa Medical interim report April – June 2018 25
Apr 25, 2018: Hansa Medical Reports January–March 2018 Results 27
Feb 14, 2018: Hansa Medical Year-End Report 2017 29
Nov 14, 2017: Hansa Medical Interim report July – September 2017 32
Jul 20, 2017: Hansa Medical Interim report April-June 2017 33
Apr 26, 2017: Hansa Medical: Interim report January – March 2017 35
Feb 15, 2017: Hansa Medical Year-End Report 2016 37
Corporate Communications 40
Mar 20, 2018: Hansa Medical Appoints Soren Tulstrup As President And CEO 40
Mar 31, 2017: Hansa Medical appoints Sam Agus as new Chief Medical Officer 41
Legal and Regulatory 42
May 19, 2017: IdeS selected for EMA Priority Medicines (PRIME) scheme 42
Product News 43
03/29/2017: Top-line clinical results from US study with lead candidate IdeS to be presented at the American Transplant Congress 43
02/14/2018: Intermediate evaluation of a sub-population in the Highdes study demonstrates good kidney function 5.5 months (median) post transplantation 44
Product Approvals 45
May 19, 2017: IdeS selected for EMA Priority Medicines (PRIME) scheme 45
Clinical Trials 46
Jan 04, 2018: Completed enrollment in Hansa Medical’s international multi-center Phase II study Highdes 46
Jan 03, 2018: Finalized Enrollment in US Phase II study with IdeS in Highly Sensitized Patients 47
Aug 02, 2017: The New England Journal of Medicine publishes results from Phase II studies of Hansa Medical’s lead candidate IdeS in highly sensitized patients 49
Jun 20, 2017: First patient treated in Phase II study with IdeS in anti-GBM antibody disease 50
Feb 16, 2017: Novel pre-clinical in vivo data demonstrate the treatment potential of IdeS in Guillain-Barre syndrome 51
Appendix 52
Methodology 52
About GlobalData 52
Contact Us 52
Disclaimer 52
List of Tables
Hansa Medical AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Hansa Medical AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Hansa Medical AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Hansa Medical AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Hansa Medical AB, Deals By Therapy Area, 2012 to YTD 2018 9
Hansa Medical AB, Medical Devices Deals, 2012 to YTD 2018 10
Hansa Medical AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Hansa Medical to Raise USD65.5 Million in Private Placement of Shares 12
Hansa Medical Plans to Raise USD21 Million in Private Placement of Shares 13
Hansa Medical Raises USD29.3 Million in Rights Offering 15
Hansa Medical Raises Funds through Private Placement of Shares 16
Hansa Medical Completes Rights Offering Of Shares For US$5.7 Million 17
Hansa Medical Completes Private Placement Of Shares For US$4 Million 18
Hansa Medical Acquires Immago Biosystems 19
Hansa Medical AB, Key Competitors 20
Hansa Medical AB, Key Employees 21
Hansa Medical AB, Subsidiaries 22
List of Figures
Hansa Medical AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Hansa Medical AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Hansa Medical AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Hansa Medical AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Hansa Medical AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Hansa Medical AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Hansa Medical AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Hansa Medical AB, Medical Devices Deals, 2012 to YTD 2018 10